Vasopressin and its immune effects in septic shock

Journal of Innate Immunity

Volumn 2, Issue 5, 2010, Pages 446-460

  Russell, James A ^a,b   Walley, Keith R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ST PAUL S HOSPITAL   (Canada)

Author keywords

Immunity; Norepinephrine; Septic shock; Vasopressin; Vasopressin receptors

Indexed keywords

CORTICOSTEROID; CORTICOTROPIN; CYCLIC AMP; HYDROCORTISONE; NORADRENALIN; PLACEBO; PROSTAGLANDIN; PURINERGIC RECEPTOR; VASOPRESSIN; VASOPRESSIN RECEPTOR; VASOPRESSIN V1A RECEPTOR; VASOPRESSIN V1B RECEPTOR; VASOPRESSIN V2 RECEPTOR;

BLOOD PRESSURE; BLOOD VESSEL TONE; BRAIN PERFUSION; CELL MEMBRANE PERMEABILITY; CLINICAL TRIAL; CREATININE CLEARANCE; DIGITAL ISCHEMIA; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG MECHANISM; GENE STRUCTURE; HEART AFTERLOAD; HEART ARREST; HEART FUNCTION; HEART OUTPUT; HEART VENTRICLE EJECTION; HUMAN; HUMORAL IMMUNITY; HYPONATREMIA; IMMUNOCOMPETENT CELL; ISCHEMIA; KIDNEY FUNCTION; LOW DRUG DOSE; MESENTERY ISCHEMIA; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEPTIC SHOCK; SIDE EFFECT; SKIN NECROSIS; UNSPECIFIED SIDE EFFECT; URINE VOLUME; VASCULAR SMOOTH MUSCLE; VASOPRESSIN RELEASE; WATER RETENTION;

ANIMALS; HUMANS; MICE; MODELS, MOLECULAR; NOREPINEPHRINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RATS; RECEPTORS, VASOPRESSIN; SHOCK, SEPTIC; TREATMENT OUTCOME; VASOPRESSINS;

EID: 77956062063     PISSN: 1662811X     EISSN: 16628128     Source Type: Journal    
DOI: 10.1159/000318531     Document Type: Review

References (115)

1. Holmes CL, Walley KR, Chittock DR, Lehman T, Russell JA: The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intensive Care Med 2001; 27: 1416-1421.
2. Kakiya S, Arima H, Yokoi H, Murase T, Yambe Y, Oiso Y: Effects of acute hypotensive stimuli on arginine vasopressin gene transcription in the rat hypothalamus. Am J Physiol Endocrinol Metab 2000; 279:E886-E892.
3. Itoi K, Jiang YQ, Iwasaki Y, Watson SJ: Regulatory mechanisms of corticotropin-releasing hormone and vasopressin gene expression in the hypothalamus. J Neuroendocrinol 2004; 16: 348-355.
4. Oliveira-Pelegrin GR, Ravanelli MI, Branco LG, Rocha MJ: Thermoregulation and vasopressin secretion during polymicrobial sepsis. Neuroimmunomodulation 2009; 16: 45-53.
5. Russell JA: Vasopressin in septic shock. Crit Care Med 2007; 35(suppl):S609-S615.
6. Landry DW, Levin HR, Gallant EM, et al: Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997; 95: 1122-1125.
7. Landry DW, Levin HR, Gallant EM, et al: Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med 1997; 25: 1279-1282.
8. Russell JA: Vasopressin in vasodilatory and septic shock. Curr Opin Crit Care 2007; 13: 383-391.
9. Lin IY, Ma HP, Lin AC, Chong CF, Lin CM, Wang TL: Low plasma vasopressin/norepinephrine ratio predicts septic shock. Am J Emerg Med 2005; 23: 718-724.
10. Russell JA, Walley KR, Singer J, et al: Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008; 358: 877-887.
11. Carnio EC, Moreto V, Giusti-Paiva A, Antunes-Rodrigues J: Neuro-immune-endocrine mechanisms during septic shock: role for nitric oxide in vasopressin and oxytocin release. Endocr Metab Immune Disord Drug Targets 2006; 6: 137-142.
12. Correa PB, Pancoto JA, de Oliveira-Pelegrin GR, Carnio EC, Rocha MJ: Participation of iNOS-derived NO in hypothalamic activation and vasopressin release during polymicrobial sepsis. J Neuroimmunol 2007; 183: 17-25.
13. Moreto V, Stabile AM, Antunes-Rodrigues J, Carnio EC: Role of heme-oxygenase pathway on vasopressin deficiency during endotoxemic shock-like conditions. Shock 2006; 26: 472-476.
14. Pancoto JA, Correa PB, Oliveira-Pelegrin GR, Rocha MJ: Autonomic dysfunction in experimental sepsis induced by cecal ligation and puncture. Auton Neurosci 2008; 138: 57-63.
15. Bruhn FH, Correa PB, Oliveira-Pelegrin GR, Rocha MJ: Blocking systemic nitric oxide production alters neuronal activation in brain structures involved in cardiovascular regulation during polymicrobial sepsis. Neurosci Lett 2009; 453: 141-146.
16. Batista MB, Bravin AC, Lopes LM, et al: Pressor response to fluid resuscitation in endotoxic shock: involvement of vasopressin. Crit Care Med 2009; 37: 2968-2972.
17. Giusti-Paiva A, Martinez MR, Bispo-da-Silva LB, Salgado MC, Elias LL, Antunes-Rodrigues J: Vasopressin mediates the pressor effect of hypertonic saline solution in endotoxic shock. Shock 2007; 27: 416-421.
18. Gomes DA, Song Z, Stevens W, Sladek CD: Sustained stimulation of vasopressin and oxytocin release by ATP and phenylephrine requires recruitment of desensitization-resistant P2X purinergic receptors. Am J Physiol Regul Integr Comp Physiol 2009; 297:R940-R949.
19. Morgenthaler NG, Muller B, Struck J, Bergmann A, Redl H, Christ-Crain M: Copeptin, a stable peptide of the arginine vasopressin precursor, is elevated in hemorrhagic and septic shock. Shock 2007; 28: 219-226.
20. Muller B, Morgenthaler N, Stolz D, et al: Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Invest 2007; 37: 145-152.
21. Lodha R, Vivekanandhan S, Sarthi M, Kabra SK: Serial circulating vasopressin levels in children with septic shock. Pediatr Crit Care Med 2006; 7: 220-224.
22. Thibonnier M, Auzan C, Madhun Z, Wilkins P, Berti-Mattera L, Clauser E: Molecular cloning, sequencing, and functional expression of a cDNA encoding the human V1a vasopressin receptor. J Biol Chem 1994; 269: 3304-3310.
23. Thibonnier M, Graves MK, Wagner MS, et al: Study of V(1)-vascular vasopressin receptor gene microsatellite polymorphisms in human essential hypertension. J Mol Cell Cardiol 2000; 32: 557-564.
24. Berrada K, Plesnicher CL, Luo X, Thibonnier M: Dynamic interaction of human vasopressin/ oxytocin receptor subtypes with G protein-coupled receptor kinases and protein kinase C after agonist stimulation. J Biol Chem 2000; 275: 27229-27237.
25. Kim SJ, Young LJ, Gonen D, et al: Transmission disequilibrium testing of arginine vasopressin receptor 1A (AVPR1A) polymorphisms in autism. Mol Psychiatry 2002; 7: 503-507.
26. Knafo A, Israel S, Darvasi A, et al: Individual differences in allocation of funds in the dictator game associated with length of the arginine vasopressin 1a receptor RS3 promoter region and correlation between RS3 length and hippocampal mRNA. Genes Brain Behav 2008; 7: 266-275.
27. Antoni FA, Holmes MC, Makara GB, Karteszi M, Laszlo FA: Evidence that the effects of arginine-8-vasopressin (AVP) on pituitary corticotropin (ACTH) release are mediated by a novel type of receptor. Peptides 1984; 5: 519-522.
28. Hernando F, Schoots O, Lolait SJ, Burbach JP: Immunohistochemical localization of the vasopressin V1b receptor in the rat brain and pituitary gland: anatomical support for its involvement in the central effects of vasopressin. Endocrinology 2001; 142: 1659-1668.
29. Lolait SJ, Stewart LQ, Jessop DS, Young WS, 3rd, O'Carroll AM: The hypothalamic-pituitary-adrenal axis response to stress in mice lacking functional vasopressin V1b receptors. Endocrinology 2007; 148: 849-856.
30. Martin K, Borgel D, Lerolle N, et al: Decreased ADAMTS-13 (A disintegrin-like and metalloprotease with thrombospondin type 1 repeats) is associated with a poor prognosis in sepsis-induced organ failure. Crit Care Med 2007; 35: 2375-2382.
31. Ono T, Mimuro J, Madoiwa S, et al: Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood 2006; 107: 528-534.
32. Schmidt C, Hocherl K, Kurt B, Bucher M: Role of nuclear factor-κ B-dependent induction of cytokines in the regulation of vasopressin V1A-receptors during cecal ligation and puncture-induced circulatory failure. Crit Care Med 2008; 36: 2363-2372.
33. Roth BL, Spitzer JA: Altered hepatic vasopressin and alpha 1-adrenergic receptors after chronic endotoxin infusion. Am J Physiol 1987; 252:E699-E702.
34. Bucher M, Hobbhahn J, Taeger K, Kurtz A: Cytokine-mediated downregulation of vasopressin V(1A) receptors during acute endotoxemia in rats. Am J Physiol Regul Integr Comp Physiol 2002; 282:R979-R984.
35. Grinevich V, Knepper MA, Verbalis J, Reyes I, Aguilera G: Acute endotoxemia in rats induces down-regulation of V2 vasopressin receptors and aquaporin-2 content in the kidney medulla. Kidney Int 2004; 65: 54-62.
36. Qahwash IM, Cassar CA, Radcliff RP, Smith GW: Bacterial lipopolysaccharide-induced coordinate downregulation of arginine vasopressin receptor V3 and corticotropin-releasing factor receptor 1 messenger ribonucleic acids in the anterior pituitary of endotoxemic steers. Endocrine 2002; 18: 13-20.
37. Barrett LK, Orie NN, Taylor V, Stidwill RP, Clapp LH, Singer M: Differential effects of vasopressin and norepinephrine on vascular reactivity in a long-term rodent model of sepsis. Crit Care Med 2007; 35: 2337-2343.
38. Yang G, Liu L, Xu J, Li T: Effect of arginine vasopressin on vascular reactivity and calcium sensitivity after hemorrhagic shock in rats and its relationship to Rho-kinase. J Trauma 2006; 61: 1336-1342.
39. Yang GM, Li T, Xu J, Ming J, Liu LM: Effect of arginine vasopressin on vascular reactivity and calcium sensitivity of vascular smooth muscle and its relationship to protein kinase C following hemorrhagic shock in rats. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2008; 20: 139-143.
40. Kawano T, Tanaka K, Nazari H, Oshita S, Takahashi A, Nakaya Y: The effects of extracellular pH on vasopressin inhibition of ATP-sensitive K+ channels in vascular smooth muscle cells. Anesth Analg 2007; 105: 1714-1719, table of contents.
41. Tiniakov R, Scrogin KE: The spleen is required for 5-HT1A receptor agonist-mediated increases in mean circulatory filling pressure during hemorrhagic shock in the rat. Am J Physiol Regul Integr Comp Physiol 2009; 296:R1392-R1401.
42. Holmes CL, Patel BM, Russell JA, Walley KR: Physiology of vasopressin relevant to management of septic shock. Chest 2001; 120: 989-1002.
43. Simon F, Giudici R, Scheuerle A, et al: Comparison of cardiac, hepatic, and renal effects of arginine vasopressin and noradrenaline during porcine fecal peritonitis: a randomized controlled trial. Crit Care 2009; 13:R113.
44. Ryckwaert F, Virsolvy A, Fort A, et al: Terlipressin, a provasopressin drug exhibits direct vasoconstrictor properties: consequences on heart perfusion and performance. Crit Care Med 2009; 37: 876-881.
45. Muller S, How OJ, Hermansen SE, Stenberg TA, Sager G, Myrmel T: Vasopressin impairs brain, heart and kidney perfusion: an experimental study in pigs after transient myocardial ischemia. Crit Care 2008; 12:R20.
46. Indrambarya T, Boyd JH, Wang Y, McConechy M, Walley KR: Low-dose vasopressin infusion results in increased mortality and cardiac dysfunction following ischemia-reperfusion injury in mice. Crit Care 2009; 13:R98.
47. Patel BM, Chittock DR, Russell JA, Walley KR: Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 2002; 96: 576-582.
48. Sawa N, Ubara Y, Katori H, et al: The longterm survival rate of catecholamine-resistant septic shock in Japanese patients who received vasopressin therapy. Clin Nephrol 2009; 72: 129-136.
49. Bragadottir G, Redfors B, Nygren A, Sellgren J, Ricksten SE: Low-dose vasopressin increases glomerular filtration rate, but impairs renal oxygenation in post-cardiac surgery patients. Acta Anaesthesiol Scand 2009; 53: 1052-1059.
50. Gordon AC, Russell JA, Walley KR, et al: The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Med 2009; 36:83-91.
51. Hocherl K, Schmidt C, Kurt B, Bucher M: Inhibition of NF-κB ameliorates sepsis-induced downregulation of aquaporin-2/V2 receptor expression and acute renal failure in vivo. Am J Physiol Renal Physiol;298:F196-F204.
52. Versteilen AM, Heemskerk AE, Groeneveld AB, van Wijhe M, van Lambalgen AA, Tangelder GJ: Mechanisms of the urinary concentration defect and effect of desmopressin during endotoxemia in rats. Shock 2008; 29: 217-222.
53. Chagnon F, Vaidya VS, Plante GE, et al: Modulation of aquaporin-2/vasopressin2 receptor kidney expression and tubular injury after endotoxin (lipopolysaccharide) challenge. Crit Care Med 2008; 36: 3054-3061.
54. Hiltebrand LB, Krejci V, Jakob SM, Takala J, Sigurdsson GH: Effects of vasopressin on microcirculatory blood flow in the gastrointestinal tract in anesthetized pigs in septic shock. Anesthesiology 2007; 106: 1156-1167.
55. Krejci V, Hiltebrand LB, Jakob SM, Takala J, Sigurdsson GH: Vasopressin in septic shock: effects on pancreatic, renal, and hepatic blood flow. Crit Care 2007; 11:R129.
56. Di Giantomasso D, Morimatsu H, Bellomo R, May CN: Effect of low-dose vasopressin infusion on vital organ blood flow in the conscious normal and septic sheep. Anaesth Intensive Care 2006; 34: 427-433.
57. Kang CH, Kim WG: The effect of vasopressin on organ blood flow in an endotoxin-induced rabbit shock model. J Invest Surg 2006; 19: 361-369.
58. Kopel T, Losser MR, Faivre V, Payen D: Systemic and hepatosplanchnic macro-and microcirculatory dose response to arginine vasopressin in endotoxic rabbits. Intensive Care Med 2008; 34: 1313-1320.
59. Knotzer H, Maier S, Dunser MW, et al: Arginine vasopressin does not alter mucosal tissue oxygen tension and oxygen supply in an acute endotoxemic pig model. Intensive Care Med 2006; 32: 170-174.
60. Nakajima Y, Baudry N, Duranteau J, Vicaut E: Effects of vasopressin, norepinephrine, and L-arginine on intestinal microcirculation in endotoxemia. Crit Care Med 2006; 34: 1752-1757.
61. Meybohm P, Cavus E, Dorges V, et al: Release of protein S100B in haemorrhagic shock: effects of small volume resuscitation combined with arginine vasopressin. Resuscitation 2008; 76: 449-456.
62. Moresi V, Garcia-Alvarez G, Pristera A, et al: Modulation of caspase activity regulates skeletal muscle regeneration and function in response to vasopressin and tumor necrosis factor. PLoS One 2009; 4:e5570.
63. Boyd JH, Kan B, Roberts H, Wang Y, Walley KR: S100A8 and S100A9 mediate endotoxininduced cardiomyocyte dysfunction via the receptor for advanced glycation end products. Circ Res 2008; 102: 1239-1246.
64. Jonkam CC, Lange M, Traber DL, et al: Cardiovascular collapse and vascular permeability changes in an ovine model of methicillin-resistant Staphylococcus aureus sepsis. Shock 2009; 32: 621-625.
65. Lange M, Hamahata A, Enkhbaatar P, et al: Assessment of vascular permeability in an ovine model of acute lung injury and pneumonia-induced Pseudomonas aeruginosa sepsis. Crit Care Med 2008; 36: 1284-1289.
66. Rehberg S, Ertmer C, Kohler G, et al: Role of arginine vasopressin and terlipressin as firstline vasopressor agents in fulminant ovine septic shock. Intensive Care Med 2009; 35: 1286-1296.
67. Zhao L, Brinton RD: Suppression of proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha in astrocytes by a V1 vasopressin receptor agonist: a cAMP response element-binding protein-dependent mechanism. J Neurosci 2004; 24: 2226-2235.
68. Boyd JH, Holmes CL, Wang Y, Roberts H, Walley KR: Vasopressin decreases sepsis-induced pulmonary inflammation through the V2R. Resuscitation 2008; 79: 325-331.
69. Chassin C, Hornef MW, Bens M, et al: Hormonal control of the renal immune response and antibacterial host defense by arginine vasopressin. J Exp Med 2007; 204: 2837-2852.
70. Hagberg L, Hull R, Hull S, McGhee JR, Michalek SM, Svanborg Eden C: Difference in susceptibility to gram-negative urinary tract infection between C3H/HeJ and C3H/HeN mice. Infect Immun 1984; 46: 839-844.
71. Banisadr G, Skrzydelski D, Kitabgi P, Rostene W, Parsadaniantz SM: Highly regionalized distribution of stromal cell-derived factor-1/CXCL12 in adult rat brain: constitutive expression in cholinergic, dopaminergic and vasopressinergic neurons. Eur J Neurosci 2003; 18: 1593-1606.
72. Shibasaki T, Hotta M, Sugihara H, Wakabayashi I: Brain vasopressin is invlolved in stress-induced suppression of immune function in the rat. Brain Res 1998;808:84-92.
73. Koike K, Sakamoto Y, Kiyama H, Masuhara K, Miyake A, Inoue M: Cytokine-induced neutrophil chemoattractant gene expression in the rat hypothalamus by osmotic stimulation. Brain Res Mol Brain Res 1997; 52: 326-329.
74. Fleisher-Berkovich S, Kagan E, Grossman N, Danon A: Multiple effects of arginine vasopressin on prostaglandin E2 synthesis in fibroblasts. Eur J Pharmacol 2004; 485: 53-59.
75. Baker C, Richards LJ, Dayan CM, Jessop DS: Corticotropin-releasing hormone immunoreactivity in human T and B cells and macrophages: colocalization with arginine vasopressin. J Neuroendocrinol 2003; 15: 1070-1074.
76. Geenen V, Defresne MP, Robert F, Legros JJ, Franchimont P, Boniver J: The neurohormonal thymic microenvironment: immunocytochemical evidence that thymic nurse cells are neuroendocrine cells. Neuroendocrinology 1988; 47: 365-368.
77. Jessop DS, Chowdrey HS, Lightman SL, Larsen PJ: Vasopressin is located within lymphocytes in the rat spleen. J Neuroimmunol 1995; 56: 219-223.
78. Wickramasinghe SN, Valdimarsson H, Williams B: Interaction between a synthetic analogue of vasopressin and human peripheral blood lymphocytes. J Clin Lab Immunol 1982; 7:67-70.
79. Chowdrey HS, Lightman SL, Harbuz MS, Larsen PJ, Jessop DS: Contents of corticotropin-releasing hormone and arginine vasopressin immunoreactivity in the spleen and thymus during a chronic inflammatory stress. J Neuroimmunol 1994; 53: 17-21.
80. Ekman R, Gobom J, Persson R, Mecocci P, Nilsson CL: Arginine vasopressin in the cytoplasm and nuclear fraction of lymphocytes from healthy donors and patients with depression or schizophrenia. Peptides 2001; 22: 67-72.
81. Bell J, Adler MW, Greenstein JI, Liu-Chen LY: Identification and characterization of [125I]arginine vasopressin binding sites on human peripheral blood mononuclear cells. Life Sci 1993; 52: 95-105.
82. Elands J, van Woudenberg A, Resink A, de Kloet ER: Vasopressin receptor capacity of human blood peripheral mononuclear cells is sex dependent. Brain Behav Immun 1990; 4: 30-38.
83. Reder AT: Regulation of production of adrenocorticotropin-like proteins in human mononuclear cells. Immunology 1992; 77: 436-442.
84. Bell J, Adler MW, Greenstein JI: The effect of arginine vasopressin on the autologous mixed lymphocyte reaction. Int J Immunopharmacol 1992; 14: 93-103.
85. Hu SB, Zhao ZS, Yhap C, et al: Vasopressin receptor 1a-mediated negative regulation of B cell receptor signaling. J Neuroimmunol 2003; 135: 72-81.
86. Yirmiya R, Shavit Y, Ben-Eliyahu S, et al: Natural killer cell activity in vasopressindeficient rats (Brattleboro strain). Brain Res 1989;479:16-22.
87. Argenziano M, Chen JM, Choudhri AF, et al: Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent. J Thorac Cardiovasc Surg 1998; 116: 973-980.
88. Dunser MW, Mayr AJ, Ulmer H, et al: The effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and postcardiotomy shock: a retrospective analysis. Anesth Analg 2001; 93: 7-13.
89. Dunser MW, Mayr AJ, Stallinger A, et al: Cardiac performance during vasopressin infusion in postcardiotomy shock. Intensive Care Med 2002; 28: 746-751.
90. Dunser MW, Mayr AJ, Ulmer H, et al: Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation 2003; 107: 2313-2319.
91. Lauzier F, Levy B, Lamarre P, Lesur O: Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial. Intensive Care Med 2006; 32: 1782-1789.
92. Luckner G, Dunser MW, Jochberger S, et al: Arginine vasopressin in 316 patients with advanced vasodilatory shock. Crit Care Med 2005; 33: 2659-2666.
93. Luckner G, Mayr VD, Jochberger S, et al: Comparison of two dose regimens of arginine vasopressin in advanced vasodilatory shock. Crit Care Med 2007; 35: 2280-2285.
94. Malay MB, Ashton RC, Jr., Landry DW, Townsend RN: Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma 1999; 47: 699-703; discussion 703-705.
95. Torgersen C, Dunser MW, Wenzel V, et al: Comparing two different arginine vasopressin doses in advanced vasodilatory shock: a randomized, controlled, open-label trial. Intensive Care Med 2009;36:57-65.
96. van Haren FM, Rozendaal FW, van der Hoeven JG: The effect of vasopressin on gastric perfusion in catecholamine-dependent patients in septic shock. Chest 2003; 124: 2256-2260.
97. Argenziano M, Chen JM, Cullinane S, et al: Arginine vasopressin in the management of vasodilatory hypotension after cardiac transplantation. J Heart Lung Transplant 1999; 18: 814-817.
98. Argenziano M, Choudhri AF, Oz MC, Rose EA, Smith CR, Landry DW: A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. Circulation 1997; 96(9 suppl):II286-II290.
99. Morales DL, Gregg D, Helman DN, et al: Arginine vasopressin in the treatment of 50 patients with postcardiotomy vasodilatory shock. Ann Thorac Surg 2000; 69: 102-106.
100. Rosenzweig EB, Starc TJ, Chen JM, et al: Intravenous arginine-vasopressin in children with vasodilatory shock after cardiac surgery. Circulation 1999; 100(19 suppl):II182-II186.
101. Chen JM, Cullinane S, Spanier TB, et al: Vasopressin deficiency and pressor hypersensitivity in hemodynamically unstable or gan donors. Circulation 1999; 100(19 suppl):I244-II246.
102. Gold J, Cullinane S, Chen J, et al: Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure. Am J Cardiol 2000; 85: 506-508, A11.
103. Klinzing S, Simon M, Reinhart K, Bredle DL, Meier-Hellmann A: High-dose vasopressin is not superior to norepinephrine in septic shock. Crit Care Med 2003; 31: 2646-2650.
104. Dunser MW, Mayr AJ, Tur A, et al: Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: in -cidence and risk factors. Crit Care Med 2003; 31: 1394-1398.
105. Hayes MA, Yau EH, Hinds CJ, Watson JD: Symmetrical peripheral gangrene: association with noradrenaline administration. Intensive Care Med 1992; 18: 433-436.
106. Rivers E, Nguyen B, Havstad S, et al: Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345: 1368-1377.
107. Russell JA, Walley KR, Gordon AC, et al: Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Crit Care Med 2009; 37: 811-818.
108. Pietranera L, Saravia F, Roig P, Lima A, De Nicola AF: Mineralocorticoid treatment upregulates the hypothalamic vasopressinergic system of spontaneously hypertensive rats. Neuroendocrinology 2004; 80: 100-110.
109. Ertmer C, Bone HG, Morelli A, et al: Methylprednisolone reverses vasopressin hyporesponsiveness in ovine endotoxemia. Shock 2007; 27: 281-288.
110. Rabadan-Diehl C, Aguilera G: Glucocorticoids increase vasopressin V1b receptor coupling to phospholipase C. Endocrinology 1998; 139: 3220-3226.
111. Tanoue A, Ito S, Honda K, et al: The vasopressin V1b receptor critically regulates hypothalamic-pituitary-adrenal axis activity under both stress and resting conditions. J Clin Invest 2004; 113: 302-309.
112. Aguilera G, Rabadan-Diehl C: Vasopressinergic regulation of the hypothalamic-pituitary-adrenal axis: implications for stress adaptation. Regul Pept 2000; 96: 23-29.
113. Bauer SR, Lam SW, Cha SS, Oyen LJ: Effect of corticosteroids on arginine vasopressincontaining vasopressor therapy for septic shock: a case control study. J Crit Care 2008; 23: 500-506.
114. Mentzelopoulos SD, Zakynthinos SG, Tzoufi M, et al: Vasopressin, epinephrine, and corticosteroids for in-hospital cardiac arrest. Arch Intern Med 2009; 169: 15-24.
115. Cagliani R, Fumagalli M, Pozzoli U, Riva S, Cereda M, Comi GP, Pattini L, Bresolin N, Sironi M: A complex selection signature at the human AVPR1B gene. BMC Evol Biol 2009; 9: 123.